Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 1:40 pm Sale |
2024-12-31 | 13G | NextCure, Inc. NXTC |
Logos Global Management LP | 0 0.000% |
-2,500,000 (Position Closed) |
Filing History |
| 2025-02-14 1:34 pm Sale |
2024-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Logos Global Management LP | 0 0.000% |
-3,500,000 (Position Closed) |
Filing History |
| 2024-11-27 2:22 pm Purchase |
2024-11-25 | 13G | GlycoMimetics, Inc. GLYC |
Logos Global Management LP | 5,000,000 7.800% |
5,000,000 (New Position) |
Filing History |
| 2024-11-14 7:13 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
Logos Global Management LP | 5,078,927 4.900% |
5,078,927 (New Position) |
Filing History |
| 2024-11-14 7:05 pm Sale |
2024-09-30 | 13G | Elevation Oncology, Inc. ELEV |
Logos Global Management LP | 3,500,000 5.900% |
-150,000 (-4.11%) |
Filing History |
| 2024-11-14 6:59 pm Purchase |
2024-09-30 | 13G | NextCure, Inc. NXTC |
Logos Global Management LP | 2,500,000 8.900% |
499,540 (+24.97%) |
Filing History |
| 2024-11-14 6:55 pm Sale |
2024-09-30 | 13G | Cybin Inc. CYBN |
Logos Global Management LP | 0 0.000% |
-1,052,632 (Position Closed) |
Filing History |
| 2024-11-14 6:51 pm Sale |
2024-09-30 | 13G | aTyr Pharma, Inc. ATYR |
Logos Global Management LP | 1,750,000 2.100% |
-4,050,000 (-69.83%) |
Filing History |
| 2024-11-14 6:46 pm Sale |
2024-09-30 | 13G | Annexon, Inc. ANNX |
Logos Global Management LP | 2,900,000 2.700% |
-4,044,444 (-58.24%) |
Filing History |
| 2024-11-14 6:40 pm Purchase |
2024-09-30 | 13G | Adverum Biotechnologies, Inc. ADVM |
Logos Global Management LP | 416,666 2.000% |
416,666 (New Position) |
Filing History |
| 2024-10-23 6:09 pm Purchase |
2024-10-16 | 13G | Bright Minds Biosciences Inc. DRUG |
Logos Global Management LP | 100,000 2.200% |
100,000 (New Position) |
Filing History |
| 2024-08-27 5:22 pm Purchase |
2024-03-14 | 13G | Cybin Inc. CYBN |
Logos Global Management LP | 1,052,632 5.300% |
1,052,632 (New Position) |
Filing History |
| 2024-08-13 6:53 pm Purchase |
2024-08-09 | 13D | Design Therapeutics, Inc. DSGN |
Logos Global Management LP | 4,232,627 7.500% |
1,420,126 (+50.49%) |
Filing History |
| 2024-06-06 6:49 pm Sale |
2024-06-04 | 13D | Olema Pharmaceuticals, Inc. OLMA |
Logos Global Management LP | 3,248,818 5.800% |
-1,018,130 (-23.86%) |
Filing History |
| 2024-04-01 6:34 pm Purchase |
2024-04-01 | 13G | NextCure, Inc. NXTC |
Logos Global Management LP | 2,000,460 7.200% |
2,000,460 (New Position) |
Filing History |
| 2024-02-22 3:47 pm Purchase |
2024-02-06 | 13G | Adverum Biotechnologies, Inc. ADVM |
Logos Global Management LP | 1,500,000 7.200% |
1,500,000 (New Position) |
Filing History |
| 2024-02-14 4:01 pm Sale |
2023-12-31 | 13G | Allakos Inc. ALLK |
Logos Global Management LP | 2,900,000 3.300% |
-2,386,666 (-45.15%) |
Filing History |
| 2024-02-14 3:51 pm Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Logos Global Management LP | 150,000 0.400% |
150,000 (New Position) |
Filing History |
| 2024-02-13 7:31 pm Sale |
2023-12-31 | 13G | IDEAYA Biosciences, Inc. IDYA |
Logos Global Management LP | 1,800,000 2.800% |
-2,100,000 (-53.85%) |
Filing History |
| 2024-02-13 7:23 pm Purchase |
2023-12-31 | 13G | Annexon, Inc. ANNX |
Logos Global Management LP | 6,944,444 8.300% |
3,844,444 (+124.01%) |
Filing History |